Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix in Adults Aged 50 Years and Older

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 137173A (Primary) ; DTaP vaccine
Indications Diphtheria; Herpes zoster; Pertussis; Poliomyelitis; Tetanus
Focus Pharmacodynamics; Registrational; Therapeutic Use
Sponsors GlaxoSmithKline; GSK

Most Recent Events

20 Aug 2019 Primary endpoint has been met. (Antibody Concentrations Against Glycoprotein E (Anti-gE))
20 Aug 2019 Primary endpoint has not been met. (Antibody Concentrations Against Pertactin (Anti-PRN) Antigens)
20 Aug 2019 Primary endpoint has been met. (Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA))

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com